Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: GlobeNewswire
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara Therapeutics (BCAX) is now covered by Bank of America Corporation. They set a "buy" rating and a $35.00 price target on the stock.MarketBeat
- Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference [Yahoo! Finance]Yahoo! Finance
- A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
BCAX
Earnings
- 11/10/25 - Miss
BCAX
Sec Filings
- 3/24/26 - Form 4
- 3/23/26 - Form 144
- 3/20/26 - Form 4
- BCAX's page on the SEC website